These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

578 related articles for article (PubMed ID: 26668268)

  • 41. A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib.
    Graziani G; Artuso S; De Luca A; Muzi A; Rotili D; Scimeca M; Atzori MG; Ceci C; Mai A; Leonetti C; Levati L; Bonanno E; Tentori L; Caccuri AM
    Biochem Pharmacol; 2015 May; 95(1):16-27. PubMed ID: 25795251
    [TBL] [Abstract][Full Text] [Related]  

  • 42. WIP Drives Tumor Progression through YAP/TAZ-Dependent Autonomous Cell Growth.
    Gargini R; Escoll M; García E; García-Escudero R; Wandosell F; Antón IM
    Cell Rep; 2016 Nov; 17(8):1962-1977. PubMed ID: 27851961
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Arterial stiffness induces remodeling phenotypes in pulmonary artery smooth muscle cells via YAP/TAZ-mediated repression of cyclooxygenase-2.
    Dieffenbach PB; Haeger CM; Coronata AMF; Choi KM; Varelas X; Tschumperlin DJ; Fredenburgh LE
    Am J Physiol Lung Cell Mol Physiol; 2017 Sep; 313(3):L628-L647. PubMed ID: 28642262
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The receptor tyrosine kinase EphA2 promotes glutamine metabolism in tumors by activating the transcriptional coactivators YAP and TAZ.
    Edwards DN; Ngwa VM; Wang S; Shiuan E; Brantley-Sieders DM; Kim LC; Reynolds AB; Chen J
    Sci Signal; 2017 Dec; 10(508):. PubMed ID: 29208682
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pro-invasive activity of the Hippo pathway effectors YAP and TAZ in cutaneous melanoma.
    Nallet-Staub F; Marsaud V; Li L; Gilbert C; Dodier S; Bataille V; Sudol M; Herlyn M; Mauviel A
    J Invest Dermatol; 2014 Jan; 134(1):123-132. PubMed ID: 23897276
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells.
    Jenkins MH; Croteau W; Mullins DW; Brinckerhoff CE
    Matrix Biol; 2015 Oct; 48():66-77. PubMed ID: 25989506
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dedifferentiation by adenovirus E1A due to inactivation of Hippo pathway effectors YAP and TAZ.
    Zemke NR; Gou D; Berk AJ
    Genes Dev; 2019 Jul; 33(13-14):828-843. PubMed ID: 31171701
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Involvement of YAP, TAZ and HSP90 in contact guidance and intercellular junction formation in corneal epithelial cells.
    Raghunathan VK; Dreier B; Morgan JT; Tuyen BC; Rose BW; Reilly CM; Russell P; Murphy CJ
    PLoS One; 2014; 9(10):e109811. PubMed ID: 25290150
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Role of YAP/TAZ transcriptional regulators in resistance to anti-cancer therapies.
    Kim MH; Kim J
    Cell Mol Life Sci; 2017 Apr; 74(8):1457-1474. PubMed ID: 27826640
    [TBL] [Abstract][Full Text] [Related]  

  • 50. BET and BRAF inhibitors act synergistically against BRAF-mutant melanoma.
    Paoluzzi L; Hanniford D; Sokolova E; Osman I; Darvishian F; Wang J; Bradner JE; Hernando E
    Cancer Med; 2016 Jun; 5(6):1183-93. PubMed ID: 27169980
    [TBL] [Abstract][Full Text] [Related]  

  • 51. BRAF
    Lunavat TR; Cheng L; Einarsdottir BO; Olofsson Bagge R; Veppil Muralidharan S; Sharples RA; Lässer C; Gho YS; Hill AF; Nilsson JA; Lötvall J
    Proc Natl Acad Sci U S A; 2017 Jul; 114(29):E5930-E5939. PubMed ID: 28684402
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The role of eIF4E in response and acquired resistance to vemurafenib in melanoma.
    Zhan Y; Dahabieh MS; Rajakumar A; Dobocan MC; M'Boutchou MN; Goncalves C; Lucy SL; Pettersson F; Topisirovic I; van Kempen L; Del Rincón SV; Miller WH
    J Invest Dermatol; 2015 May; 135(5):1368-1376. PubMed ID: 25615552
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Transcriptional co-repressor function of the hippo pathway transducers YAP and TAZ.
    Kim M; Kim T; Johnson RL; Lim DS
    Cell Rep; 2015 Apr; 11(2):270-82. PubMed ID: 25843714
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis.
    Parmenter TJ; Kleinschmidt M; Kinross KM; Bond ST; Li J; Kaadige MR; Rao A; Sheppard KE; Hugo W; Pupo GM; Pearson RB; McGee SL; Long GV; Scolyer RA; Rizos H; Lo RS; Cullinane C; Ayer DE; Ribas A; Johnstone RW; Hicks RJ; McArthur GA
    Cancer Discov; 2014 Apr; 4(4):423-33. PubMed ID: 24469106
    [TBL] [Abstract][Full Text] [Related]  

  • 55. YAP/TAZ regulates the expression of proteoglycan 4 and tenascin C in superficial-zone chondrocytes.
    Delve E; Co V; Regmi SC; Parreno J; Schmidt TA; Kandel RA
    Eur Cell Mater; 2020 Jan; 39():48-64. PubMed ID: 31917459
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Flow-dependent YAP/TAZ activities regulate endothelial phenotypes and atherosclerosis.
    Wang KC; Yeh YT; Nguyen P; Limqueco E; Lopez J; Thorossian S; Guan KL; Li YJ; Chien S
    Proc Natl Acad Sci U S A; 2016 Oct; 113(41):11525-11530. PubMed ID: 27671657
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Vemurafenib potently induces endoplasmic reticulum stress-mediated apoptosis in BRAFV600E melanoma cells.
    Beck D; Niessner H; Smalley KS; Flaherty K; Paraiso KH; Busch C; Sinnberg T; Vasseur S; Iovanna JL; Drießen S; Stork B; Wesselborg S; Schaller M; Biedermann T; Bauer J; Lasithiotakis K; Weide B; Eberle J; Schittek B; Schadendorf D; Garbe C; Kulms D; Meier F
    Sci Signal; 2013 Jan; 6(260):ra7. PubMed ID: 23362240
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The BRAFT1799A mutation confers sensitivity of thyroid cancer cells to the BRAFV600E inhibitor PLX4032 (RG7204).
    Xing J; Liu R; Xing M; Trink B
    Biochem Biophys Res Commun; 2011 Jan; 404(4):958-62. PubMed ID: 21185263
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Hepatocyte growth factor renders BRAF mutant human melanoma cell lines resistant to PLX4032 by downregulating the pro-apoptotic BH3-only proteins PUMA and BIM.
    Rohrbeck L; Gong JN; Lee EF; Kueh AJ; Behren A; Tai L; Lessene G; Huang DC; Fairlie WD; Strasser A; Herold MJ
    Cell Death Differ; 2016 Dec; 23(12):2054-2062. PubMed ID: 27689874
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The oncogenic BRAF kinase inhibitor PLX4032/RG7204 does not affect the viability or function of human lymphocytes across a wide range of concentrations.
    Comin-Anduix B; Chodon T; Sazegar H; Matsunaga D; Mock S; Jalil J; Escuin-Ordinas H; Chmielowski B; Koya RC; Ribas A
    Clin Cancer Res; 2010 Dec; 16(24):6040-8. PubMed ID: 21169256
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.